Adverse Drug Events after Kidney Transplantation

Lionel Rostaing, Thomas Jouvé, Florian Terrec, Paolo Malvezzi, Johan Noble

Journal of Personalized Medicine · 2023 · 28 citations · 52 references

DOIFull text

Open access

Concepts

Abstract

Introduction: Kidney transplantation stands out as the optimal treatment for patients with end-stage kidney disease, provided they meet specific criteria for a secure outcome. With the exception of identical twin donor–recipient pairs, lifelong immunosuppression becomes imperative. Unfortunately, immunosuppressant drugs, particularly calcineurin inhibitors like tacrolimus, bring about adverse effects, including nephrotoxicity, diabetes mellitus, hypertension, infections, malignancy, leukopenia, anemia, thrombocytopenia, mouth ulcers, dyslipidemia, and wound complications. Since achieving tolerance is not feasible, patients are compelled to adhere to lifelong immunosuppressive therapies, often involving calcineurin inhibitors, alongside mycophenolic acid or mTOR inhibitors, with or without steroids. Area covered: Notably, these drugs, especially calcineurin inhibitors, possess narrow therapeutic windows, resulting in numerous drug-related side effects. This review focuses on the prevalent immunosuppressive drug-related side effects encountered in kidney transplant recipients, namely nephrotoxicity, post-transplant diabetes mellitus, leukopenia, anemia, dyslipidemia, mouth ulcers, hypertension, and viral reactivations (cytomegalovirus and BK virus). Additionally, other post-kidney-transplantation drugs such as valganciclovir may also contribute to adverse events such as leukopenia. For each side effect, we propose preventive measures and outline appropriate treatment strategies.

References

52

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus11This study was sponsored by a grant from Fujisawa USA, Deerfield, Illinois.22The authors were working on behalf of the Tacrolimus US Heart Transplant Multicenter Study Group. Other members of the Study Group included (principal investigator listed first): UTAH Cardiac Transplant Program, Salt Lake City, Utah: David O. Taylor, MD, Dale G. Renlund, MD, Abdallah G. Kfoury, MD; St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas: O. H. Frazier, MD, Branislav Radovancevic, MD, Edward K. Massin, MD; University of Wisconsin Hospitals and Clinics, Madison, Wisconsin: Robert M. Mentzer, Jr., MD, Charles C. Canver, MD, Robert B. Love, MD; Ochsner Medical Foundation, New Orleans, Louisiana: Frank W. Smart, MD, Hector O. Ventura, MD, Dwight D. Stapleton, MD, Mandeep Mehra, MD; University of Southern California, Los Angeles, California: Mark L. Barr, MD, Vaugh A. Starnes, MD; Medical College of Virginia, Richmond, Virginia: David E. Tolman, MD, Albert Guerraty, MD, David Salter, MD; Cleveland Clinic Foundation, Cleveland, Ohio: James B. Young, MD; Data Management and Statistical Coordinating Center-The EMMES Corporation, Potomac, Maryland: Paul VanVeldhuisen, MS, Anne Lindblad, PhD, Anita Yaffe, MSN, MPH.

David O. Taylor, Mark L. Barr, Branislav Radovančević et al. · The Journal of Heart and Lung Transplantation · 1999 · 320 citations

, , +16